Shruthi Mahalingaiah, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polycystic Ovary Syndrome | 10 | 2024 | 383 | 4.290 |
Why?
|
Menstrual Cycle | 10 | 2024 | 542 | 3.110 |
Why?
|
Endocrine Disruptors | 7 | 2022 | 264 | 2.770 |
Why?
|
Cosmetics | 3 | 2023 | 102 | 2.000 |
Why?
|
Menarche | 3 | 2024 | 538 | 1.990 |
Why?
|
Environmental Exposure | 17 | 2024 | 4533 | 1.600 |
Why?
|
Menstruation Disturbances | 5 | 2024 | 143 | 1.590 |
Why?
|
Air Pollution | 9 | 2023 | 2364 | 1.470 |
Why?
|
Air Pollutants | 11 | 2023 | 2905 | 1.450 |
Why?
|
Fertilization in Vitro | 7 | 2022 | 1297 | 1.360 |
Why?
|
Reproductive Techniques, Assisted | 2 | 2024 | 502 | 1.340 |
Why?
|
Environmental Pollutants | 7 | 2024 | 1290 | 1.300 |
Why?
|
Infertility, Female | 3 | 2024 | 764 | 1.280 |
Why?
|
Fertility | 5 | 2024 | 772 | 1.190 |
Why?
|
Abortion, Spontaneous | 4 | 2019 | 539 | 1.120 |
Why?
|
Phenols | 3 | 2019 | 520 | 1.020 |
Why?
|
Ovulation Induction | 2 | 2024 | 277 | 0.990 |
Why?
|
Malus | 2 | 2022 | 51 | 0.980 |
Why?
|
Pregnancy Rate | 3 | 2017 | 655 | 0.960 |
Why?
|
Hair Preparations | 2 | 2021 | 32 | 0.920 |
Why?
|
Benzophenones | 1 | 2024 | 57 | 0.910 |
Why?
|
Ovary | 2 | 2019 | 960 | 0.860 |
Why?
|
Phthalic Acids | 3 | 2024 | 483 | 0.850 |
Why?
|
Menstruation | 2 | 2023 | 310 | 0.850 |
Why?
|
Tetrachloroethylene | 3 | 2020 | 7 | 0.850 |
Why?
|
Hypoparathyroidism | 1 | 2024 | 136 | 0.850 |
Why?
|
Information Seeking Behavior | 1 | 2024 | 116 | 0.840 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 2022 | 47 | 0.800 |
Why?
|
Oocytes | 2 | 2024 | 1168 | 0.790 |
Why?
|
Pregnancy | 28 | 2024 | 30179 | 0.790 |
Why?
|
Cryopreservation | 2 | 2024 | 731 | 0.770 |
Why?
|
Pregnancy Outcome | 6 | 2023 | 2959 | 0.710 |
Why?
|
Benzhydryl Compounds | 3 | 2019 | 939 | 0.690 |
Why?
|
Hirsutism | 1 | 2020 | 68 | 0.690 |
Why?
|
Endometriosis | 3 | 2022 | 873 | 0.660 |
Why?
|
Leiomyoma | 2 | 2014 | 640 | 0.640 |
Why?
|
Premature Birth | 4 | 2024 | 1816 | 0.630 |
Why?
|
Water Pollutants, Chemical | 3 | 2020 | 363 | 0.610 |
Why?
|
Prenatal Exposure Delayed Effects | 4 | 2020 | 2538 | 0.570 |
Why?
|
Ecosystem | 1 | 2021 | 494 | 0.570 |
Why?
|
Female | 65 | 2024 | 396943 | 0.560 |
Why?
|
Women's Health | 4 | 2024 | 2079 | 0.540 |
Why?
|
Gastroesophageal Reflux | 1 | 2023 | 833 | 0.520 |
Why?
|
Metformin | 1 | 2023 | 914 | 0.500 |
Why?
|
Nurses | 3 | 2022 | 2494 | 0.500 |
Why?
|
Reproduction | 2 | 2018 | 646 | 0.500 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2015 | 108 | 0.490 |
Why?
|
Metabolome | 1 | 2022 | 1009 | 0.490 |
Why?
|
Uterine Neoplasms | 2 | 2014 | 1422 | 0.490 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1207 | 0.480 |
Why?
|
Diabetes, Gestational | 1 | 2024 | 1259 | 0.470 |
Why?
|
Infertility | 1 | 2020 | 654 | 0.440 |
Why?
|
Diethylstilbestrol | 1 | 2013 | 87 | 0.440 |
Why?
|
Menopause | 3 | 2021 | 1651 | 0.440 |
Why?
|
Fetal Development | 1 | 2019 | 771 | 0.430 |
Why?
|
Vehicle Emissions | 2 | 2017 | 656 | 0.430 |
Why?
|
Maternal Exposure | 3 | 2024 | 1078 | 0.420 |
Why?
|
Qualitative Research | 1 | 2024 | 3115 | 0.420 |
Why?
|
Metabolomics | 1 | 2022 | 1675 | 0.410 |
Why?
|
Particulate Matter | 7 | 2023 | 2614 | 0.410 |
Why?
|
Plastics | 1 | 2012 | 119 | 0.390 |
Why?
|
Oocyte Retrieval | 2 | 2024 | 160 | 0.390 |
Why?
|
Ovulation | 2 | 2023 | 181 | 0.380 |
Why?
|
Humans | 65 | 2024 | 768451 | 0.380 |
Why?
|
Adult | 35 | 2024 | 223542 | 0.380 |
Why?
|
Culture Media | 1 | 2012 | 899 | 0.350 |
Why?
|
Pilot Projects | 5 | 2023 | 8730 | 0.340 |
Why?
|
Cohort Studies | 14 | 2024 | 41797 | 0.330 |
Why?
|
Young Adult | 14 | 2024 | 60045 | 0.310 |
Why?
|
Electronic Health Records | 2 | 2024 | 4877 | 0.300 |
Why?
|
Follicle Stimulating Hormone | 3 | 2024 | 726 | 0.280 |
Why?
|
Luteinizing Hormone | 3 | 2024 | 821 | 0.270 |
Why?
|
Preconception Care | 2 | 2017 | 143 | 0.250 |
Why?
|
United States | 11 | 2024 | 73121 | 0.240 |
Why?
|
Anti-Mullerian Hormone | 3 | 2022 | 415 | 0.240 |
Why?
|
Counseling | 2 | 2024 | 1548 | 0.230 |
Why?
|
North America | 2 | 2020 | 1292 | 0.230 |
Why?
|
Adolescent | 11 | 2024 | 89168 | 0.230 |
Why?
|
Alabama | 1 | 2024 | 112 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2834 | 0.230 |
Why?
|
Placenta Diseases | 2 | 2017 | 199 | 0.220 |
Why?
|
Educational Status | 1 | 2011 | 2519 | 0.220 |
Why?
|
Inositol | 1 | 2024 | 216 | 0.220 |
Why?
|
Soaps | 1 | 2023 | 29 | 0.210 |
Why?
|
Perimenopause | 1 | 2024 | 142 | 0.210 |
Why?
|
Hypocalcemia | 1 | 2024 | 203 | 0.210 |
Why?
|
Menorrhagia | 1 | 2022 | 59 | 0.200 |
Why?
|
Contraceptive Agents | 1 | 2023 | 147 | 0.200 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2022 | 117 | 0.190 |
Why?
|
Hypercalcemia | 1 | 2024 | 423 | 0.190 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 12242 | 0.190 |
Why?
|
Prospective Studies | 9 | 2024 | 54914 | 0.190 |
Why?
|
Oils | 1 | 2021 | 56 | 0.190 |
Why?
|
Hazardous Substances | 1 | 2022 | 153 | 0.190 |
Why?
|
Fertilization | 1 | 2022 | 198 | 0.190 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12561 | 0.180 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26351 | 0.180 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 367 | 0.180 |
Why?
|
Progesterone | 2 | 2024 | 750 | 0.180 |
Why?
|
Progestins | 1 | 2022 | 302 | 0.180 |
Why?
|
Chorionic Gonadotropin | 1 | 2022 | 458 | 0.180 |
Why?
|
Internet | 2 | 2024 | 3123 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15638 | 0.170 |
Why?
|
Age Factors | 3 | 2024 | 18478 | 0.170 |
Why?
|
Ultraviolet Rays | 2 | 2022 | 1100 | 0.170 |
Why?
|
Endometrium | 1 | 2022 | 407 | 0.170 |
Why?
|
Patient Selection | 1 | 2011 | 4266 | 0.160 |
Why?
|
Patient Education as Topic | 2 | 2024 | 2339 | 0.160 |
Why?
|
New York | 1 | 2021 | 882 | 0.160 |
Why?
|
Fluorocarbons | 1 | 2024 | 505 | 0.150 |
Why?
|
Chromatography, Liquid | 1 | 2022 | 998 | 0.150 |
Why?
|
Infant, Newborn | 6 | 2024 | 26395 | 0.150 |
Why?
|
Self Report | 2 | 2020 | 3771 | 0.150 |
Why?
|
Infant, Low Birth Weight | 1 | 2023 | 875 | 0.150 |
Why?
|
Embryo Transfer | 1 | 2022 | 524 | 0.150 |
Why?
|
Boston | 5 | 2021 | 9361 | 0.150 |
Why?
|
Seasons | 1 | 2023 | 1526 | 0.150 |
Why?
|
Climate Change | 1 | 2024 | 510 | 0.140 |
Why?
|
Acetaminophen | 1 | 2021 | 556 | 0.140 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2022 | 1149 | 0.140 |
Why?
|
Time Factors | 5 | 2024 | 40271 | 0.130 |
Why?
|
Health Surveys | 2 | 2017 | 4056 | 0.130 |
Why?
|
Residence Characteristics | 2 | 2017 | 2119 | 0.130 |
Why?
|
Middle Aged | 10 | 2024 | 223418 | 0.120 |
Why?
|
Pregnancy Trimester, First | 2 | 2024 | 918 | 0.120 |
Why?
|
Stillbirth | 2 | 2017 | 376 | 0.120 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2204 | 0.120 |
Why?
|
Longevity | 1 | 2022 | 1077 | 0.120 |
Why?
|
Birth Weight | 1 | 2023 | 2117 | 0.120 |
Why?
|
Body Mass Index | 2 | 2024 | 13030 | 0.120 |
Why?
|
Massachusetts | 5 | 2021 | 8908 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 4049 | 0.120 |
Why?
|
Estrogens | 1 | 2021 | 1531 | 0.110 |
Why?
|
ROC Curve | 1 | 2022 | 3624 | 0.110 |
Why?
|
Canada | 2 | 2016 | 2143 | 0.110 |
Why?
|
Child | 5 | 2024 | 80863 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2024 | 81834 | 0.110 |
Why?
|
Patient Compliance | 2 | 2015 | 2696 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2103 | 0.110 |
Why?
|
Ectogenesis | 1 | 2012 | 8 | 0.110 |
Why?
|
Prolactin | 2 | 2021 | 626 | 0.100 |
Why?
|
Embryo Implantation | 2 | 2011 | 272 | 0.100 |
Why?
|
Logistic Models | 2 | 2022 | 13324 | 0.100 |
Why?
|
Forecasting | 1 | 2022 | 2950 | 0.100 |
Why?
|
Risk Factors | 6 | 2024 | 74915 | 0.100 |
Why?
|
Emotions | 1 | 2024 | 2773 | 0.100 |
Why?
|
Bone Remodeling | 1 | 2015 | 583 | 0.100 |
Why?
|
Bariatric Surgery | 1 | 2022 | 1007 | 0.100 |
Why?
|
DDT | 1 | 2011 | 32 | 0.100 |
Why?
|
Hexachlorobenzene | 1 | 2011 | 27 | 0.100 |
Why?
|
Limit of Detection | 1 | 2012 | 277 | 0.100 |
Why?
|
Particle Size | 1 | 2016 | 1654 | 0.090 |
Why?
|
Caffeine | 1 | 2016 | 702 | 0.090 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14766 | 0.090 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 1 | 2011 | 86 | 0.090 |
Why?
|
Suction | 1 | 2012 | 268 | 0.090 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 267 | 0.090 |
Why?
|
Calcium | 1 | 2024 | 5793 | 0.090 |
Why?
|
Incidence | 4 | 2020 | 21552 | 0.090 |
Why?
|
Solubility | 1 | 2012 | 1086 | 0.090 |
Why?
|
Hypoglycemic Agents | 1 | 2023 | 3111 | 0.090 |
Why?
|
Drug Design | 1 | 2015 | 1050 | 0.090 |
Why?
|
Hormone Replacement Therapy | 1 | 2015 | 756 | 0.090 |
Why?
|
Age of Onset | 1 | 2016 | 3342 | 0.080 |
Why?
|
Animals | 7 | 2023 | 169418 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2659 | 0.080 |
Why?
|
Polychlorinated Biphenyls | 1 | 2011 | 236 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2012 | 1543 | 0.080 |
Why?
|
Blood Pressure | 1 | 2024 | 8538 | 0.080 |
Why?
|
Androgens | 1 | 2015 | 1285 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1669 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2014 | 1464 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6353 | 0.070 |
Why?
|
Obesity | 3 | 2024 | 13065 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10358 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20231 | 0.070 |
Why?
|
Tandem Mass Spectrometry | 1 | 2012 | 1197 | 0.070 |
Why?
|
Comprehension | 1 | 2011 | 641 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39430 | 0.060 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 473 | 0.060 |
Why?
|
Macaca mulatta | 2 | 2022 | 2363 | 0.060 |
Why?
|
Life Style | 1 | 2015 | 3929 | 0.060 |
Why?
|
Algorithms | 1 | 2024 | 14158 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9382 | 0.050 |
Why?
|
Male | 9 | 2023 | 364781 | 0.050 |
Why?
|
Risk Assessment | 2 | 2016 | 24311 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12096 | 0.050 |
Why?
|
Benzene | 1 | 2022 | 107 | 0.050 |
Why?
|
Testosterone | 2 | 2024 | 2493 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8753 | 0.050 |
Why?
|
Alkanesulfonic Acids | 1 | 2024 | 203 | 0.050 |
Why?
|
Pregnancy Trimester, Third | 1 | 2024 | 583 | 0.050 |
Why?
|
Pregnancy Trimester, Second | 1 | 2024 | 738 | 0.050 |
Why?
|
Linear Models | 1 | 2011 | 5880 | 0.050 |
Why?
|
Sperm Count | 1 | 2022 | 229 | 0.050 |
Why?
|
Follicular Fluid | 1 | 2021 | 92 | 0.050 |
Why?
|
Formaldehyde | 1 | 2022 | 361 | 0.050 |
Why?
|
Sperm Motility | 1 | 2022 | 266 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2024 | 708 | 0.040 |
Why?
|
Perioperative Period | 1 | 2021 | 252 | 0.040 |
Why?
|
Semen Analysis | 1 | 2022 | 236 | 0.040 |
Why?
|
Periodicity | 1 | 2021 | 348 | 0.040 |
Why?
|
Semen | 1 | 2022 | 349 | 0.040 |
Why?
|
Testis | 1 | 2022 | 783 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 7066 | 0.040 |
Why?
|
Thyrotropin | 1 | 2021 | 834 | 0.040 |
Why?
|
Hot Temperature | 1 | 2024 | 1439 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2011 | 2969 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1668 | 0.030 |
Why?
|
Estradiol | 1 | 2024 | 1949 | 0.030 |
Why?
|
Abruptio Placentae | 1 | 2017 | 118 | 0.030 |
Why?
|
Uterine Hemorrhage | 1 | 2017 | 240 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2008 | 4419 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2017 | 464 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2358 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1724 | 0.030 |
Why?
|
Quality of Life | 1 | 2015 | 13497 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22293 | 0.030 |
Why?
|
Demography | 1 | 2018 | 1643 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1638 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14728 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3615 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3708 | 0.020 |
Why?
|
Pain Measurement | 1 | 2021 | 3577 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 2021 | 1763 | 0.020 |
Why?
|
Beverages | 1 | 2016 | 822 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2024 | 3974 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 11930 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 962 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2008 | 359 | 0.020 |
Why?
|
Pre-Eclampsia | 1 | 2017 | 1257 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2008 | 268 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 178 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12450 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7451 | 0.020 |
Why?
|
Signal Transduction | 1 | 2008 | 23638 | 0.010 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 561 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2011 | 65409 | 0.010 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2008 | 792 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10601 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2014 | 3590 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 8081 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6217 | 0.010 |
Why?
|
Infant | 1 | 2023 | 36497 | 0.010 |
Why?
|
Smoking | 1 | 2018 | 9099 | 0.010 |
Why?
|
Prevalence | 1 | 2018 | 15880 | 0.010 |
Why?
|
Blotting, Western | 1 | 2008 | 5042 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2008 | 6241 | 0.010 |
Why?
|
Child, Preschool | 1 | 2018 | 42623 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15609 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 59680 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 19041 | 0.010 |
Why?
|
Aged | 1 | 2018 | 171520 | 0.000 |
Why?
|
Mice | 1 | 2008 | 82045 | 0.000 |
Why?
|